Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
AstraZeneca
Moodys
McKinsey
Boehringer Ingelheim

Last Updated: October 21, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Fulranumab

See Plans and Pricing

« Back to Dashboard

Development status for investigational drug Fulranumab: Patents, clinical trial progress, indications

Fulranumab is an investigational drug.

There have been 4 clinical trials for Fulranumab. The most recent clinical trial was a Phase 3 trial, which was initiated on March 1st 2015.

The most common disease conditions in clinical trials are Osteoarthritis and [disabled in preview]. The leading clinical trial sponsors are Janssen Research & Development, LLC and [disabled in preview].

There are four US patents protecting this investigational drug and two hundred and seventy-five international patents.

Recent Clinical Trials for Fulranumab
TitleSponsorPhase
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3003Janssen Research & Development, LLCPhase 3
Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001Janssen Research & Development, LLCPhase 3
Study of Efficacy, Safety of Fulranumab Monotherapy for OA of Hip or Knee, PAI3002Janssen Research & Development, LLCPhase 3

See all Fulranumab clinical trials

Clinical Trial Summary for Fulranumab

Top disease conditions for Fulranumab
Top clinical trial sponsors for Fulranumab

See all Fulranumab clinical trials

US Patents for Fulranumab

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Fulranumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Fulranumab   Start Trial Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein CureVac AG (Tubingen, DE)   Start Trial
Fulranumab   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
Fulranumab   Start Trial Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients Corning Incorporated (Corning, NY)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Fulranumab

Drugname Country Document Number Estimated Expiration Related US Patent
Fulranumab Australia 2013220749 2032-02-15   Start Trial
Fulranumab Brazil 112014019627 2032-02-15   Start Trial
Fulranumab Canada 2862476 2032-02-15   Start Trial
Fulranumab China 104114705 2032-02-15   Start Trial
Fulranumab China 108570468 2032-02-15   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Moodys
Boehringer Ingelheim
McKesson
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.